NextCure (NASDAQ:NXTC) Lowered to “Strong Sell” Rating by Zacks Research

NextCure (NASDAQ:NXTC) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of NextCure in a research report on Monday, April 27th. Three analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $23.00.

NextCure Price Performance

Shares of NextCure stock opened at $10.18 on Wednesday. The business has a fifty day simple moving average of $11.31 and a two-hundred day simple moving average of $11.67. NextCure has a 1 year low of $4.44 and a 1 year high of $15.74. The company has a market capitalization of $36.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.43.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping the consensus estimate of ($2.10) by $0.23. As a group, equities analysts anticipate that NextCure will post -8.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Exome Asset Management LLC bought a new position in NextCure during the 4th quarter worth $2,341,000. Marshall Wace LLP bought a new position in shares of NextCure in the fourth quarter worth $160,000. Affinity Asset Advisors LLC increased its position in shares of NextCure by 28.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after purchasing an additional 55,412 shares during the period. Ikarian Capital LLC bought a new position in shares of NextCure in the fourth quarter worth $3,382,000. Finally, Squadron Capital Management LLC bought a new position in shares of NextCure in the fourth quarter worth $3,363,000. Institutional investors own 42.65% of the company’s stock.

About NextCure

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.